Propanc Biopharma Secures up to $100 million for Crypto Treasury

189
SHARES
1.5k
VIEWS

Related articles


Australia-based Propanc Biopharma has introduced that it has secured $100 million from a crypto-focused household workplace to launch a crypto treasury — a transfer its CEO described as “transformative” as its most cancers remedy product enters human trials subsequent 12 months. 

The non-public placement, structured by convertible most popular inventory, gives Propanc with an preliminary $1 million funding and as much as $99 million in follow-on funding over the following 12 months from Hexstone Capital, a household workplace that invests in a number of crypto treasury firms.

The cancer-treating biotech firm stated that the proceeds will probably be used to construct a digital asset treasury and speed up the event of its lead most cancers remedy, PRP, which goals to enter first-in-human trials within the second half of 2026.

Propanc CEO James Nathanielsz mentioned the crypto treasury would help a “transformative section” for the corporate by strengthening its stability sheet and advancing its proenzyme-based oncology platform. 

“We are able to goal not solely sufferers affected by metastatic most cancers from strong tumors, however a number of persistent illnesses primarily based upon the mechanism of motion of proenzyme remedy.”

Whereas Propanc didn’t say which digital belongings it plans to purchase for its crypto treasury, Hexstone’s purchasers have invested in every thing from Bitcoin (BTC), Ether (ETH), Solana (SOL), Injective (INJ) in addition to some lesser-known cryptocurrencies.

Biotech firms adopting a crypto technique

Propanc joins Sonnet BioTherapeutics, Sharps Know-how and different biotech firms which have turned to crypto to reignite investor curiosity.